Publications by authors named "Maria-Jose Requena"

Claim this Profile
B
Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer.
Meritxell Pérez, Juan José Lozano, Mercedes Ingelmo-Torres, Montserrat Domenech, Caterina Fernández Ramón, Maria José Requena

Biomedicines· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.
Joseba Salguero, Enrique Gómez-Gómez, José Valero-Rosa, Julia Carrasco-Valiente, Juan Mesa, María José Requena

Korean J Radiol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study.
Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, María José Requena, Javier López-Jiménez

Br J Haematol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Impact of the use of simulators on the mental workload and confidence in a digital rectal examination and bladder catheterization workshop.].
Julia Carrasco, Enrique Gómez, José Horacio García, José Valero, Alvaro Sánchez, María José Requena

Arch Esp Urol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, Pilar Giraldo, Manuel Pérez-Encinas, María-José Requena

Cancer Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Carlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, Francisco Javier Díaz, Eva González-Barca, María José Requena

Clin Lymphoma Myeloma Leuk· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Valentin García-Gutiérrez, Jose Manuel Puerta, Begoña Maestro, Luis Felipe Casado Montero, Alfonso Muriel, Maria José Requena

Am J Hematol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired hemophilia A: three different presentations of the same disease.
Raquel del Campo, Juan Bargay, Antonia Cladera, Humbelina Balaguer, Maria José Requena

Blood Coagul Fibrinolysis· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A Canales, Guillermo Deben, María-José Requena

Haematologica· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous pancreas-kidney transplant: a single-center long-term outcome.
María Luisa Aguera, María Dolores Navarro, Rodrigo Pérez-Calderón, Alberto Rodríguez-Benot, Raquel Ojeda, María José Requena

J Nephrol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis